Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Latest Information Update: 23 May 2023
At a glance
- Drugs Anastrozole (Primary) ; Buserelin (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Nafarelin (Primary) ; Tamoxifen (Primary) ; Toremifene (Primary) ; Triptorelin (Primary)
- Indications Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- 17 May 2023 Planned initiation date changed from 1 Apr 2023 to 1 Jun 2023.
- 10 Apr 2023 New trial record